Although about half of CHF patients have a preserved EF, no meds have been shown to improve patient outcomes. This industry sponsored RCT of >4000 patients, age >60, with CHF and EF > 45% found no difference in mortality or cardiovascular hospitalization between those randomized to irbesartan or placebo (consistent across all measured subgroups) after mean f/u of >4 years. The irbesartan patients were more likely to have at least 1 measured doubling of creatinine. There is no clear role for ARBs in normal EF CHF (abstract).
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]
By reading the headlines recently, practitioners would not know if they saved or tanked the healthcare system. One day disaster looms, the next we have moderated growth and business can continue as usual (and by business, I mean doing the correct things correctly). A new study, along with some recent data, helps shed some light […]